RARA and acute myeloid leukemia: Their biological effects on LSCs were at least partly mediated by Notch4. Conversely, a pan-RAR antagonist delayed leukemogenesis and reduced stemness of EVI1high AML, suggesting potential novel treatment options for this aggressive AML subtype.